The role of blinatumomab post-HCT is currently being evaluated in a number of single arm, open label studies, including a multi-centre Canadian phase II study using blinatumomab for treatment of detectable MRD in the first year following allogeneic HCT for patients with B-ALL (NCT#04044560), as well as studies examining TCRαβ and CD45RA depleted haploidentical HCT followed by blinatumomab in the early post-engraftment period and TCRαβ/CD19-depleted haploidentical HCT followed by CD45RA-depleted DLI and blinatumomab in pediatric patients with CD19+ malignancy (NCT#02790515 and NCT#03849651). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.